Companies · Pharmaceuticals

Honest Globe Inc.

SANTA ANA · Pharmaceuticals

Diligence memoA one-page analyst read on Honest Globe Inc. — recommendation, valuation, rhythm, risks.
$15.0M
Total raised · real
1
Rounds
Latest step-up
Top 40%
Sector rank · raised
Series A
Latest stage · inferred · Wed Jul 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Honest Globe Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 3.05× the median modeled value of Series A Pharmaceuticals companies in 2019–2021 (76 peers) — value vs value, same stage and era.
Dormant
  • Last raise 6.0 yr ago; this sector typically re-raises about every 13 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Honest Globe Inc. is one of 1613 Pharmaceuticals companies tracked from SANTA ANA. By capital raised it ranks mid-pack (ahead of 61% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$1M–$5M
Issuer revenue
Rule 506(c)
Reg D exemption
2015
Year incorporated
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2020-07-01 Raised $15M (real) Modeled valuation $465M (est)$15M$465MSeries A2020

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$15.0M · 2020

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$464.6M
Base estimate est.
$17.2M
Conservative case
$2.5B
Upside case
$68.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
6.0 yr
Elapsed time used
6.0 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
6.0 yr
On record since
2020
First round
1
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.9× above median
This company$15.0M
Sector median$8.1M
Latest round — vs other Series A rounds in sector (real $, this stage) 2.9× above median
This company$15.0M
Sector median$5.2M
Modeled value — vs sector median (estimate, all stages) 6.1× above median
This company$464.6M
Sector median$76.1M

Raised more than 61% of sector peers (real $). Modeled value above 80% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #2 of 76.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Xynomic Pharmaceuticals Holdings, Inc. · Series A Raised $15.0M · modeled $464.6M (est)Athenen Therapeutics, Inc. · Series A Raised $12.0M · modeled $371.7M (est)Zomedica Pharmaceuticals Corp. · Series A Raised $25.6M · modeled $371.7M (est)CerSci Therapeutics Inc. · Series A Raised $12.0M · modeled $371.7M (est)Rational Vaccines, Inc. · Series A Raised $27.8M · modeled $363.5M (est)Primmune Therapeutics, Inc. · Series A Raised $20.1M · modeled $350.3M (est)Aytu Bioscience, Inc · Series A Raised $28.8M · modeled $309.7M (est)Solaris Pharma Corp · Series A Raised $23.4M · modeled $309.7M (est)Ally Therapeutics, Inc. · Series A Raised $10.0M · modeled $309.7M (est)Avitide, Inc. · Series A Raised $40.9M · modeled $309.7M (est)PharmAbbie, Inc. · Series A Raised $15.0M · modeled $282.0M (est)Honest Globe Inc. (this company) Raised $15.0M · modeled $464.6M (est)Honest Globe Inc.
CompanyStageRaised · realValue · estvs peer med.
Xynomic Pharmaceuticals Holdings, Inc.Series A$15.0M$464.6M3.05×
Honest Globe Inc. this companySeries A$15.0M$464.6M3.05×
Athenen Therapeutics, Inc.Series A$12.0M$371.7M2.44×
Zomedica Pharmaceuticals Corp.Series A$25.6M$371.7M2.44×
CerSci Therapeutics Inc.Series A$12.0M$371.7M2.44×
Rational Vaccines, Inc.Series A$27.8M$363.5M2.38×
Primmune Therapeutics, Inc.Series A$20.1M$350.3M2.30×
Aytu Bioscience, IncSeries A$28.8M$309.7M2.03×
Solaris Pharma CorpSeries A$23.4M$309.7M2.03×
Ally Therapeutics, Inc.Series A$10.0M$309.7M2.03×
Avitide, Inc.Series A$40.9M$309.7M2.03×
PharmAbbie, Inc.Series A$15.0M$282.0M1.85×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$15.0M2020-07-01$68.2M$464.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$15.0M2020-07-01
    • First recorded raise — entered as Series A.
Intelligence
Modeled next raise
$24.0M
Modeled next size est.range $15.6M$38.4M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Eyal Kotler1 other2020-07
Registry & provenance

Honest Globe Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1806669
SEC CIK
2015
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Arbutus Biopharma CorpPharmaceuticalsSeries A$15.0M$464.6Msame sector · same stage
PharmAbbie, Inc.PharmaceuticalsSeries A$15.0M$282.0Msame sector · same stage
Rvc 360, LlcPharmaceuticalsSeries A$15.0M$464.6Msame sector · same stage
Sinocom Pharmaceutical, Inc.PharmaceuticalsSeries A$15.0M$464.6Msame sector · same stage
Vitae Pharmaceuticals, IncPharmaceuticalsSeries A$15.0M$464.6Msame sector · same stage
Xynomic Pharmaceuticals Holdings, Inc.PharmaceuticalsSeries A$15.0M$464.6Msame sector · same stage
Dauntless 1, Inc.PharmaceuticalsSeries A$15.0M$247.8Msame sector · same stage
CHINA BAICAOTANG MEDICINE LtdPharmaceuticalsSeries A$15.3M$276.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Globeimmune IncPharmaceuticalsSeries B$71.4M84%
Response Pharmaceuticals, Inc.PharmaceuticalsSeries A$20.5M79%
Sea Pharmaceuticals, LLCPharmaceuticalsSeed$5.3M78%
Cambridge Therapeutic Technologies, LLCPharmaceuticalsSeries A$185.8M78%
Sermonix Pharmaceuticals, Inc.PharmaceuticalsSeries C$878.7M78%
Concordia International Corp.PharmaceuticalsSeries D+$8.1B78%
Shuttle Pharmaceuticals Holdings, Inc.PharmaceuticalsSeries A$7.1M78%
LeafBio, Inc.PharmaceuticalsSeries A$27.9M77%
Frequently asked
How much funding has Honest Globe Inc. raised?
Honest Globe Inc. has raised approximately $15.0M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Honest Globe Inc.'s estimated valuation?
Provath's modeled valuation for Honest Globe Inc. is approximately $464.6M (modeled range $17.2M–$2.5B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Honest Globe Inc. at?
Honest Globe Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Wed Jul 01.
What does Honest Globe Inc. do and where is it based?
Honest Globe Inc. operates in the Pharmaceuticals sector, based in SANTA ANA.
Explore related

See where Honest Globe Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Honest Globe Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.